LN-isobutyrylcysteine (L-NIBC) bound gold cluster Au18(L-NIBC)14, its composition and use
L-NIBC-conjugated gold cluster molecules, particularly Au 18(L-NIBC) 14, are characterized and purified for effective pharmaceutical use, addressing the variability in gold clusters to treat multiple sclerosis, Alzheimer's disease, cirrhosis, diabetes mellitus, and Parkinson's disease.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- SHENZHEN PROFOUND VIEW PHARMA TECH CO LTD
- Filing Date
- 2022-01-20
- Publication Date
- 2026-06-19
AI Technical Summary
The variability in the number of gold atoms and ligands in gold clusters complicates the identification of specific gold cluster molecules with therapeutic potential, limiting their application in drug development for diseases such as multiple sclerosis, Alzheimer's disease, cirrhosis, diabetes mellitus, and Parkinson's disease.
The development of L-N-isobutyrylcysteine (L-NIBC)-conjugated gold cluster molecules, specifically Au 18(L-NIBC) 14, which are characterized and purified to a high degree of purity, enabling their use in pharmaceutical compositions for treating these diseases.
The Au 18(L-NIBC) 14 molecules demonstrate significant therapeutic effects in animal models of multiple sclerosis, Alzheimer's disease, cirrhosis, diabetes mellitus, and Parkinson's disease, improving clinical scores and reducing disease symptoms.
Smart Images
Figure 0007876224000003 
Figure 0007876224000004 
Figure 0007876224000005